Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval…
Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful partnership with IFundWomen in 2023, this year marks the second…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA)…
Leading global pharmaceutical company Lupin Limited (Lupin) has announced the introduction of Ganirelix Acetate Injection, 250 mcg mL, Single-Dose Prefilled Syringe, following approval from the United States Food and Drug Administration (U.S. FDA). This generic equivalent to the reference listed…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) revealed today that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its experimental drug olezarsen. This designation is specifically for the treatment of familial chylomicronemia syndrome (FCS), a…
Today marks the completion of GSK’s acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company dedicated to addressing the unmet medical needs of patients with respiratory and inflammatory conditions. As previously disclosed, this acquisition encompasses AIO-001, a promising long-acting anti-thymic…
Zoetis, a global leader in animal health, has announced its financial results for the fourth quarter and full year 2023, along with full-year guidance for 2024. In the fourth quarter of 2023, Zoetis reported revenue of $2.2 billion, marking an…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for treating patients aged 12 and older with severe sickle cell…
Bristol Myers Squibb has disclosed that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro™ (repotrectinib) to treat adult and pediatric patients aged 12 and above with solid tumors containing a neurotrophic…
Today marks the completion of AbbVie’s acquisition of ImmunoGen (NASDAQ: IMGN), solidifying ImmunoGen’s integration into AbbVie’s portfolio. Robert A. Michael, AbbVie’s president and chief operating officer, expressed enthusiasm about the merger, stating, “Together with ImmunoGen, we have the potential to…
Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA). This solution serves as a generic equivalent to BromSite® Ophthalmic Solution,…
CRISPR Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company dedicated to pioneering transformative gene-based therapies for serious illnesses, has announced a strategic move in securing approximately $280 million through a registered direct offering of its common shares. This offering, set at…
